Table 1. Patient characteristics and outcomes.
| N | Adenoma size (mm) | Adenoma pathology | Duct involved | Intraductal extension (mm) | Intraductal pathology | RFA sessions (n) | Concomitant therapies | Biliary stents (n) | Follow-up from papillectomy (mo) | Follow-up from 1 st RFA (mo) |
| 1 | 20 | HGD with intramucosal adenocarcinoma | CBD | 6 | Adenocarcinoma | 1 | – | 2 | 47 | 46 |
| 2 | 8 | LGD | CBD | 6 | LGD | 4 | APC (4^ session) | 2 | 44 | 42 |
| 3 | 40 (pedunculated) | LGD | CBD | Present on histology only | LGD | 1 | – | 2 | 32 | 31 |
| 4 | 16 | HGD | CBD | Present on histology only | LGD | 2 | APC (2^ session) | 2 | 25 | 20 |
| 5 | 14 | HGD | CBD | 13 | HGD | 2 | – | 2 | 24 | 24 |
| 6 | 16 | LGD | CBD | 6 | LGD (serrated) | 1 | APC | 2 | 23 | 21 |
| 7 | 18 | HGD | CBD | Present on histology only | HGD | 1 | APC | 3 | 79 | 20 |
| 8 | 25 | LGD | CBD + PD | 9 + 9 | LGD | 2 | APC | 3 | 20 | 19 |
| 9 | 17 | HGD | CBD | 14 | HGD | 1 | – | 3 | 41 | 13 |
APC, argon plasma coagulation; HGD, high-grade dysplasia; LGD, low-grade dysplasia; mo, months; CBD, common bile duct; PD, pancreatic duct; RFA, radio frequency ablation.